THE ROLE OF INTERLEUKIN-1 AND ASSOCIATED CYTOKINES IN GASTRIC CARCINOGENESIS

Cover Page

Abstract


This review presents detailed analysis of scientific data on influence of the associated with interleukin-1 cytokines on the development of malignant tumors of stomach with the definition of spectrum of diagnostic and therapeutic possibilities. Cytokines associated with interleukin-1 directly and indirectly involved into gastric carcinogenesis. Implementation of pro- and contreoncogenic effects depends on many factors. The serological and genetic criteria changes of interleukin-1 have high diagnostic value and prognostic significance opening new differential approaches to the treatment of precancer conditions and gastric cancer.

 


About the authors

L. V. Matveeva

Medical Institute of N.P. Ogarev Mordovian State University, Saransk, Russian Federation

Author for correspondence.
Email: MatveevaLjubov1@mail.ru

Russian Federation кандидат медицинских наук, доцент кафедры иммунологии, микробиологии и виру- сологии медицинского института МГУ им. Н.П. Огарева Адрес: 430032, Республика Мордовия, г. Саранск, ул. Ульянова, д. 26а Тел.: (8342) 35-25-16

L. M. Mosina

Medical Institute of N.P. Ogarev Mordovian State University, Saransk, Russian Federation

Email: lardoc@rambler.ru

Russian Federation доктор медицинских наук, профессор кафедры госпитальной терапии медицинского института МГУ им. Н.П. Огарева Адрес: 430032, Республика Мордовия, Саранск, ул. Ульянова, д. 26а Тел.: (8342) 32-19-83

References

  1. Statistics of malignant tumors in Russia and the CIS in 2009. Vestn. RONTs im. N.N. Blokhina RAMN = Bulletin of N.N. Blokhin RCRC. 2011; 22 (3, app. 1): 172.
  2. Sims J.E., Nicklin M.J., Bazan J.F., Barton J.L., Busfield S.J., Ford J.E., Kastelein R.A., Kumar S., Lin H., Mulero J.J., Pan J., Pan Y., Smith D.E., Young P.R. A new nomenclature for IL-1-family genes. Trends Immunol. 2001; 22: 536–537.
  3. Tebloeva L.M., Dmitrieva L.A., Grigoryan S.S., Gurevich K.G. New members of the cytokine interleukin-1 and its role in the destructive inflammatory diseases. Med. al'manakh = Med. almanac. 2011; 5 (18): 274–276.
  4. Ferrari D., Pizzirani C., Adinolfi E.. Lemoli R.M., Curti A., IdzkoM., Panther E., Di Virgilio F. The P2X7 receptor: a key player in ИЛ-1 processing and release. J. Immunol. 2006; 176: 3877–3883.
  5. Giraldo S., Sanchez J., Felty Q., Roy D. IL-1B. Atlas of genetics and cytogenetics in oncology and haematology. 2008. URL:http://AtlasGeneticsOncology.org/Genes/ИЛ1BID40950ch2q13.html
  6. Serebrennikova S.N., Seminskii I.Zh. The role of cytokines in the inflammatory process (message 1). Sib. med. zhurn. = Siberian medical journal. 2008; 6: 5–8.
  7. Ageeva E.S., Shtygasheva O.V., Pulikov A.S., Butorin N.N. The role of IL-1 and IL-8 in pathomorphism gastric mucosa in Helicobacter pylori-associated gastritis. Byull. VSNTs SO RAMN = Bulletin of ESRC SD RAMS. 2011; 1 (77): 16–20.
  8. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 2008; 223: 20–38.
  9. Dinarello C.A., Fantuzzi G. Interleukin-18 and host defense against infection. J. Infect. Dis. 2003; 187 (2): 370–384.
  10. Alboni S., Cervia D., Sugama S., Conti B. Interleukin-18 in the CNS. J. Neuroinflammation. 2010; 7: 9–13.
  11. Kozlov V.K. Tsitokinoterapiya: patogeneticheskaya napravlennost' pri infektsionnykh zabolevaniyakh i klinicheskaya effektivnost': Ruk-vo dlya vrachei [Cytokine therapy: pathogenetic focus in infectious diseases and clinical efficacy: Guide for physicians]. St.Petersburg, Al'ter Ego, 2010. 148 p.
  12. Freindlin I.S., Sheikin Yu.A. Endothelial cells as targets and producing cytokines. Med. immunologiya = Med. Immunology. 2001; 3 (4): 499–514.
  13. Starikova E.A., Amchislavskii E.I., Sokolov D.I., Freidlin I.S., Polosukhina E.R. Baryshnikov A.Yu. Changes in the surface phenotype of endothelial cells under the influence of pro-inflammatory and anti-inflammatory cytokines. Med. immunologiya = Med. Immunology. 2003; 5 (1–2): 39–48.
  14. Ketlinskii S.A., Simbirtsev A.S., Vorob'ev A.A. Endogennye immunomodulyatory [Endogenous Immunomodulators]. St.Petersburg, Gippokrat, 1992. 256 p.
  15. Severin E.S., Aleinikova T.L., Osipov E.V., Silaeva S.A. Biologicheskaya khimiya [Biological Chemistry]. Moscow, MIA, 2008. 364 p.
  16. Walecka-Kapica E., Knopik-Dabrowicz A., Klupinska G., Chojnacki J. The assessment of nitric oxide metabolites in gastric juice in Helicobacter pylori infected subjects in compliance with grade of inflammatory lesions in gastric mucosa. Pol. Merkur. Lekarski. 2008; 24 (140): 95–100.
  17. Richikesh M.K., Sadhana S.S. Prostaglandins and cyclooxygenase: their probable role in cancer. Indian J. Farmacol. 2003; 35: 3–12.
  18. Tringali G., Pozzoli G., Vairano M., Mores N., Preziosi P., Navarra P. Interleukin-18 displays effects opposite to those of interleukin-1 in the regulation of neuroendocrine stress axis. J. Neuroimmunol. 2005; 160 (1): 61–67.
  19. Tkach S.M. H. pylori infection as the main cause of gastric carcinogenesis. Zdorov'e Ukrainy = Health of Ukraine. 2009; 1: 32–33.
  20. Fox J.G., Wang T.C. Inflammation, atrophy and gastric cancer. J. Clin. Invest. 2007; 117: 60–69.
  21. McColl K.E., El-Omar E., Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol. Clin. North Am. 2000; 29: 687–703.
  22. Maev I.V., Kucheryavyi Yu.A., Oganesyan T.S. Allelic polymorphism of interleukin-1β at gelikobakterioza. Ros. zhurn. gastroenterol., gepatol., koloproktol. = Russian journal of gastroenterology, hepatology and colopractology. 2008; 5: 4–11.
  23. Saperas E., Tache Y. Central interleukin-1 beta-induced inhibition of acid secretion in rats: specificity of action. Life Sci. 1993; 52: 785–792.
  24. Hitzler I., Sayi A., Kohler E., Engler D. B., Koch K.N., Hardt W.D., Muller A. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1β and IL-18. J. Immunol. 2012; 188 (8): 3594–3602.
  25. Bartchewsky W. Jr., Martini M.R., Masiero M., Squassoni A.C., Alvarez M.C., Ladeira M.S., Salvatore D., Trevisan M., Pedrazzoli J.Jr. Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand. J. Gastroenterol. 2009; 44 (2): 153–161.
  26. Day A.S., Su B., Ceponis P.J., Jones N.L., Yau E., Sieveking D., Sherman P.M. Helicobacter pylori infection induces interleukin-18 production in gastric epithelial (AGS) cells. Dig. Dis. Sci. 2004; 49 (11–12): 1830–1835.
  27. Seino H., Ueda H., Kokai M., Tsuji N.M., Kashiwamura S., Morita Y., Okamura H. IL-18 mediates the formation of stress-induced, histamine-dependent gastric lesions. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292 (1): 262–267.
  28. Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., Betz K.S., Penz-Oesterreicher M., Bjorkdahl O., Fox J.G., Wang T.C. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer cell. 2008; 14 (5): 408–419.
  29. Berezhnaya N.M. The role of immune system cells in the tumor microenvironment. II. The interaction of cells of the immune system with the other components of the microenvironment. Onkolog. = Oncology. 2009; 11 (2): 86–93.
  30. Kadagidze Z.G. Cytokines. Prakt. onkolog. = Practical oncology. 2003; 4 (3): 131–139.
  31. Teletaeva G.M. Cytokines and anti-tumor immunity. Prakt. onkolog. = Practical oncology. 2007; 8 (4): 211–218.
  32. Iigo M., Shimamura M., Matsuda E., Fujita K., Nomoto H., Satoh J., Kojima S., Alexander D.B., Moore M.A., Tsuda H. Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa a possible explanation for inhibition of carcinogenesis and metastasis. Cytocine. 2004; 25: 36–44.
  33. Cao R., Farnebo J., Kurimoto M., Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. The FASEB J. 1999; 13 (15): 2195–2202.
  34. Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J. Leucocyte Biol. 2003; 73: 213–214.
  35. Sakai K., Kita M., Sawai N., Shiomi S., Sumida Y., Kanemasa K. Levels of interleukin-18 are markedly increased in Helicobacter pylori-infected gastric mucosa among patients with specific IL-18 genotypes. J. Inf. Dis. 2008; 197 (12): 1752–1761.
  36. Park S., Cheon S., Cho D. The dual effects of interleukin-18 in tumor progression. Cell. Mol. Immunol. 2007; 4 (5): 329–335.
  37. Macri A., Versaci A., Loddo S., Scuderi G., Travagliante M., Trimarchi G., Teti D., Famulari C. Serum levels of interleukin-1 beta, interleukin-8 and tumor necrosis factor alpha as marcers of gastric cancer. Biomarcers. 2006; 11 (2): 184–193.
  38. Sun P., Ben Q., Tu S., Dong W., Qi X., Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 2011; 56 (12): 3596–3601.
  39. Anisimova N.Yu., Gromova E.G., Kuznetsova L.S., Dolzhikova Yu.I., Boiko N.I., Titov K.S., Antonov A.K., Kiselevskii M.V. Interleukin-17 and interleukin-18 as biomarkers of sepsis in cancer patients. Vestn. sl. krovi Rossii = Bulletin of Russian blood service. 2011; 4: 30–33.
  40. Hwang I.R., Kodama T., Kikuchi S., Sakai K., Peterson L.E., Graham D.Y., Yamaoka Y. Effect of interleukin 1 polimorphisms on gastric mucosal interleukin-1 beta production in Helicobacter pylori infection. Gasrtoenterology. 2002; 123 (6): 1793–1803.
  41. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Younq H.A., Herrera J., Lissowska J., Yuan C.C., Rothman N., Lanyon G., Martin M., Fraumeni J.F., Rabkin C.S. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000; 404 (6776): 398–402.
  42. El-Omar E.M., Rabkin C.S., Gammon M.D., Vaughan T.L., Risch H.A., Schoenberg J.B., Stanford J.L., Mayne S.T., Goedert J., Blot W.J., Fraumeni J.F., Chow W.H. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003; 124: 1193–1201.
  43. Al-Moundhri M.S., Al-Nabhani M., Al-Bahrani B., Burney I.A., Al-Madhani A., Ganquly S.S., Al-Yahyaee S.A., Grant C.S. Intreleukin-1 beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphismus and gastric cancer risk in an Omani Arab population. Gastric Cancer. 2006; 9 (4): 284–290.
  44. Machado J.C., Pharoah P., Sousa S. Interleukin-1β and interleukin-1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001; 121 (4): 823–829.
  45. Zeng Z.R., Hu P.J., Hu S., Pang R.P., Chen M.H., Ng M., Sung J. J. Y. Association of interleukin IL-1β gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut. 2003; 52: 1684–1689.
  46. Chen A., Li C.N., Hsu P.I., Lai K.H., Tseng H.H., Hsu P.N., Lo G.H., Lo C.C., Lin C.K., Hwang I.R., Yamaoka Y., Chen H.C. Risks of interleukin-1 genetic polymorphisms and Helicobacter pylori infection in the development of gastric cancer. Aliment. Pharmacol. Ther. 2004; 20: 203–211.
  47. Garza-Gonzalez E., Bosques-Padilla F.J., El-Omar E., Hold G., Tijerina-Menchaca R., Maldonado-Garza H.J., Perez-Perez G.I. Role of polymorphic IL-1B, IL-1RN, and TNF-A genes in distal gastric cancer in Mexico. Int. J. Cancer. 2005; 114: 237–241.
  48. Lee S.G., Kim B., Choi W., Lee I., Choi J., Song K. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B31 C/+ and IL-1RN*2/*2) and gastric cancer/duodenal ulcer in Korean population. Cytokine. 2003; 21: 167.
  49. Matsukura N., Yamada S., Kato S., Tomtitchong P., Tajiri T., Miki M., Matsuhisa T., Yamada N. Genetic differences in interleukin-1β polymorphisms among four Asian populations: an analysis of the Asian paradox between H. pylori infection and gastric cancer incidence. J. Exp. Clin. Cancer Res. 2003; 22: 47–55.
  50. Furuta T., Shirai N., Sugimoto M. Controversy in polymorphisms of interleukin-1β in gastric cancer risks. J. Gastroenterol. 2004; 39: 501–503.

Statistics

Views

Abstract - 283

PDF (Russian) - 895

Cited-By


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies